# COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

> **NCT05518487** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 15 (actual)

## Conditions studied

- COVID-19
- Kidney Transplant

## Interventions

- **BIOLOGICAL:** Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine

## Key facts

- **NCT ID:** NCT05518487
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-20
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-11-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-06-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05518487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05518487, "COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05518487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*